Which of the following statements by a client who is at 8 weeks of gestation and is Rh-negative indicates an understanding of the teaching about the Rho(D) immune globulin injection?

Choice A reason: Rho(D) immune globulin is administered after a miscarriage in Rh-negative women to prevent isoimmunization, as fetal blood mixing can occur. This immunoglobulin neutralizes Rh-positive fetal antigens, preventing maternal antibody formation that could affect future pregnancies. The immune response could otherwise lead to hemolytic disease in subsequent Rh-positive fetuses. Choice B reason: Administering Rho(D) immune globulin at 12 weeks is not standard practice. It is typically given at 28 weeks and post-delivery or after events like miscarriage. Early administration is unnecessary unless a sensitizing event occurs, as maternal-fetal blood mixing is rare before the third trimester, per immunological principles. Choice C reason: Rho(D) immune globulin does not prevent preterm labor, which is driven by uterine or hormonal factors. The injection targets Rh isoimmunization by neutralizing Rh-positive fetal antigens. Preterm labor involves prostaglandin and oxytocin pathways, unrelated to Rh sensitization, making this statement irrelevant to the immunoglobulin’s immunological mechanism. Choice D reason: Rho(D) immune globulin is unnecessary post-delivery if the baby is Rh-negative, as no sensitization occurs without Rh-positive fetal blood. The injection is given only if the baby is Rh-positive to prevent maternal antibody formation. This statement reflects a misunderstanding of Rh immunology and isoimmunization risk in pregnancy.